189 related articles for article (PubMed ID: 17350571)
1. Wild-type p53: tumors can't stand it.
Kastan MB
Cell; 2007 Mar; 128(5):837-40. PubMed ID: 17350571
[TBL] [Abstract][Full Text] [Related]
2. p53 mutation heterogeneity in cancer.
Soussi T; Lozano G
Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer.
Van Maerken T; Rihani A; Van Goethem A; De Paepe A; Speleman F; Vandesompele J
Cancer Lett; 2014 Mar; 344(2):157-65. PubMed ID: 24262662
[TBL] [Abstract][Full Text] [Related]
4. The p53 mutation "gradient effect" and its clinical implications.
Zambetti GP
J Cell Physiol; 2007 Nov; 213(2):370-3. PubMed ID: 17671971
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53: an oncogenic transcription factor.
Strano S; Dell'Orso S; Di Agostino S; Fontemaggi G; Sacchi A; Blandino G
Oncogene; 2007 Apr; 26(15):2212-9. PubMed ID: 17401430
[TBL] [Abstract][Full Text] [Related]
6. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation.
Wang Y; Suh YA; Fuller MY; Jackson JG; Xiong S; Terzian T; Quintás-Cardama A; Bankson JA; El-Naggar AK; Lozano G
J Clin Invest; 2011 Mar; 121(3):893-904. PubMed ID: 21285512
[TBL] [Abstract][Full Text] [Related]
7. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.
Giuriato S; Ryeom S; Fan AC; Bachireddy P; Lynch RC; Rioth MJ; van Riggelen J; Kopelman AM; Passegué E; Tang F; Folkman J; Felsher DW
Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16266-71. PubMed ID: 17056717
[TBL] [Abstract][Full Text] [Related]
8. Strategies for manipulating the p53 pathway in the treatment of human cancer.
Hupp TR; Lane DP; Ball KL
Biochem J; 2000 Nov; 352 Pt 1(Pt 1):1-17. PubMed ID: 11062053
[TBL] [Abstract][Full Text] [Related]
9. Dissecting p53 tumor suppressor function in vivo through the analysis of genetically modified mice.
Johnson TM; Attardi LD
Cell Death Differ; 2006 Jun; 13(6):902-8. PubMed ID: 16557272
[No Abstract] [Full Text] [Related]
10. The p53 tumor suppressor gene and gene product.
Levine AJ
Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
[TBL] [Abstract][Full Text] [Related]
11. The oncogenic roles of p53 mutants in mouse models.
Lozano G
Curr Opin Genet Dev; 2007 Feb; 17(1):66-70. PubMed ID: 17208429
[TBL] [Abstract][Full Text] [Related]
12. [Study of the molecular mechanisms controlling activity of protein p53 in the development of new strategies in cancer therapeutics].
Marine Ch
Bull Mem Acad R Med Belg; 2009; 164(5-6):175-80; discussion 180-1. PubMed ID: 20666148
[TBL] [Abstract][Full Text] [Related]
13. [NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY].
Shuvalov OY; Fedorova OA; Petukhov AV; Daks AA; Vasilieva EA; Grigorieva TA; Ivanov GS; Barlev NA
Tsitologiia; 2015; 57(12):847-54. PubMed ID: 26995961
[TBL] [Abstract][Full Text] [Related]
14. [p53 as a molecular target for cancer therapy].
Ishioka C; Osada M; Gamo M; Kanamaru R
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2207-12. PubMed ID: 9422063
[TBL] [Abstract][Full Text] [Related]
15. p53 Replacement Therapy for Cancer.
Tazawa H; Kagawa S; Fujiwara T
Recent Results Cancer Res; 2016; 209():1-15. PubMed ID: 28101684
[TBL] [Abstract][Full Text] [Related]
16. Induction of p53 renders ATM-deficient mice refractory to hepatocarcinogenesis.
Teoh N; Pyakurel P; Dan YY; Swisshelm K; Hou J; Mitchell C; Fausto N; Gu Y; Farrell G
Gastroenterology; 2010 Mar; 138(3):1155-65.e1-2. PubMed ID: 19919837
[TBL] [Abstract][Full Text] [Related]
17. [The p53 gene and protein in 2005: new results, promising opportunities].
Szoke D; Sipos F; Spisák S; Molnár B; Tulassay Z
Orv Hetil; 2005 Jul; 146(30):1587-94. PubMed ID: 16136736
[TBL] [Abstract][Full Text] [Related]
18. Transcription regulation by mutant p53.
Weisz L; Oren M; Rotter V
Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of replicative immortality.
Yaswen P; MacKenzie KL; Keith WN; Hentosh P; Rodier F; Zhu J; Firestone GL; Matheu A; Carnero A; Bilsland A; Sundin T; Honoki K; Fujii H; Georgakilas AG; Amedei A; Amin A; Helferich B; Boosani CS; Guha G; Ciriolo MR; Chen S; Mohammed SI; Azmi AS; Bhakta D; Halicka D; Niccolai E; Aquilano K; Ashraf SS; Nowsheen S; Yang X
Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S104-S128. PubMed ID: 25869441
[TBL] [Abstract][Full Text] [Related]
20. Combining intracellular antibodies to restore function of mutated p53 in cancer.
Chan G; Jordaan G; Nishimura RN; Weisbart RH
Int J Cancer; 2016 Jan; 138(1):182-6. PubMed ID: 26174762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
